AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
2.225
-0.085 (-3.68%)
Mar 31, 2025, 1:11 PM EDT - Market open

Company Description

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.

The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc.
AbCellera Biologics logo
Country Canada
Founded 2012
IPO Date Dec 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 596
CEO Carl Hansen

Contact Details

Address:
150 West 4th Ave
Vancouver, BC V5Y 1G6
Canada
Phone 604 559 9005
Website abcellera.com

Stock Details

Ticker Symbol ABCL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001703057
CUSIP Number 00288U106
ISIN Number CA00288U1066
SIC Code 2834

Key Executives

Name Position
Dr. Carl L.G. Hansen Ph.D. Chief Executive Officer, President and Chairperson
Andrew Booth M.B.A. Chief Financial Officer
Dr. Veronique Lecault Ph.D. Chief Technology Officer and Director
Tryn T. Stimart Esq., J.D., M.Sc. Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary and Privacy Officer
Marcie Thiessen CPA, CGA Senior Director of Finance and Accounting
Tiffany Chiu B.Sc., Ph.D. Vice President of Communications
Graham Craig M.Sc. Director of Corporate Development
Murray McCutcheon Ph.D. Senior Vice President of Partnering
Neil Aubuchon B.A., M.B.A. Chief Commercial Officer
Adam Clarke M.A.I.C.D., Ph.D. Senior Vice President of Discovery

Latest SEC Filings

Date Type Title
Feb 27, 2025 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Feb 27, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 18, 2025 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 10-Q Quarterly Report
Nov 4, 2024 8-K Current Report
Oct 9, 2024 SCHEDULE 13G/A Filing
Aug 6, 2024 10-Q Quarterly Report